These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1905084)

  • 1. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
    Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
    Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct capture of plasma factor VIII:C by ion exchange chromatography.
    Teh LC; Froger M
    Vox Sang; 1994; 67(1):8-13. PubMed ID: 7975461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separation of antihemophilic factor VII from human plasma by column chromatography.
    Baikar VM; Kamath MV; Vishwanathan C; Varadkar AM; Bharmal SE
    Indian J Clin Biochem; 2003 Jan; 18(1):80-6. PubMed ID: 23105376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.
    Burnouf-Radosevich M; Burnouf T
    Vox Sang; 1992; 62(1):1-11. PubMed ID: 1580062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography.
    Josic D; Schwinn H; Stadler M; Strancar A
    J Chromatogr B Biomed Appl; 1994 Dec; 662(2):181-90. PubMed ID: 7719474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
    Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
    J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
    Branović K; Gebauer B; Trescec A; Benko B
    Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of factor VIII/von Willebrand factor from human plasma on immobilized lentil lectin.
    Zhou FL; Burnouf-Radosevich M; Burnouf T
    Protein Expr Purif; 1994 Apr; 5(2):138-43. PubMed ID: 8054845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
    Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
    Schwinn H; Smith A; Wolter D
    Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in large-scale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
    Mori F; Nardini I; Rossi P; Nardini C; Farina C
    Vox Sang; 2008 Nov; 95(4):298-307. PubMed ID: 19138259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
    Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
    Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and small-scale production of a severely heated factor VIII concentrate.
    Knevelman A; de Wit HJ; Potstra P; vd Does JA
    Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of coagulation factor VIII using chromatographic methods. Direct chromatography of plasma in anion exchange resins.
    Cheng E; Jinzenji D; Lorthiois AP; de Carvalho RR; Tanaka-Azevedo AM; Raw I; Martins EA
    Biotechnol Lett; 2010 Sep; 32(9):1207-14. PubMed ID: 20431912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
    Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.